… prostate cancer are most likely to benefit from being administered abiraterone. Abiraterone (Zytiga … metastatic castration-resistant prostate cancer (mCRPC) that … of ADT for prostate cancer patients. Researchers … with advanced prostate cancer that has …

… prostate cancer. Part of what makes prostate cancer … Prostate Cancer Genetic testing is becoming an integral part of prostate cancer … points.” In prostate cancer, certain inherited … prostate cancer treatments, such as androgen receptor pathway inhibitors Zytiga …

… for prostate cancer in men older than 70. Why? Prostate cancer tends … much better at detecting prostate tumors in the body … described as having oligometastatic prostate cancer. Q. What treatment … different mechanism called abiraterone (Zytiga). If the cancer …

… patients with metastatic castration-resistant prostate cancer point to the agent’ … patients with metastatic castration-resistant prostate cancer,” according to the investigators. … cohort (48%) received abiraterone acetate (Zytiga) as a prior therapy, whereas …

Lower-dose abiraterone acetate (Zytiga) demonstrated comparable efficacy to … patients with metastatic castration-resistant prostate cancer (mCRPC), according to … patients with metastatic castration resistant prostate cancer: A multicentric randomized phase …

… de novo metastatic hormone-sensitive prostate cancer and the treatment landscape for … rise in diagnoses of advanced prostate cancer. Several factors contribute to this … anti-androgens such as abiraterone (Zytiga) or enzalutamide (Xtandi) are standard …

… disease and consider additional treatment. Prostate Cancer Surgery Question: In what … docetaxel) or additional androgen drugs (Zytiga [abiraterone]) to treat the cancer … surgery if localized, aggressive prostate cancer potentially recurs and becomes hormone …

… treatments: Prostate cancer symptoms Most men are diagnosed with prostate cancer before they … risk management group. Is prostate cancer curable? Prostate cancer is often curable if it … with other hormone therapies like Zytiga, or even chemotherapy, depending …

… men with metastatic hormone-sensitive prostate cancer have not received recommended … and ARPIs such as abiraterone (Zytiga, Janssen) enzalutamide (Xtandi; Astellas … men with metastatic hormone-sensitive prostate cancer. They reported at ASCO Genitourinary …

… inhibitor (ARPI) rechallenge in prostate cancer due to resistance mechanisms that … a well-documented phenomenon in prostate cancer, and agents within this … -resistant prostate cancer (mCRPC) who had previously received abiraterone acetate (Zytiga). The …